RIGL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RIGL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Rigel Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2023 was $3.8 Mil. Rigel Pharmaceuticals's Average Total Inventories for the quarter that ended in Dec. 2023 was $5.8 Mil. Rigel Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.65.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Rigel Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 was 140.05.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Rigel Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.16.
The historical data trend for Rigel Pharmaceuticals's Inventory Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rigel Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Inventory Turnover | Get a 7-Day Free Trial | 0.81 | 0.60 | 0.26 | 0.22 | 0.97 |
Rigel Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Inventory Turnover | Get a 7-Day Free Trial | 0.04 | 0.10 | 0.10 | 0.15 | 0.65 |
Rigel Pharmaceuticals's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as
Inventory Turnover (A: Dec. 2023 ) | |||||||
= | Cost of Goods Sold | / | Average Total Inventories | ||||
= | Cost of Goods Sold (A: Dec. 2023 ) | / ( | (Total Inventories (A: Dec. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) |
= | 7.11 | / ( | (9.118 | + | 5.522) | / | 2 ) |
= | 7.11 | / | 7.32 | ||||
= | 0.97 |
Rigel Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as
Inventory Turnover (Q: Dec. 2023 ) | |||||||
= | Cost of Goods Sold | / | Average Total Inventories | ||||
= | Cost of Goods Sold (Q: Dec. 2023 ) | / ( | (Total Inventories (Q: Sep. 2023 ) | + | Total Inventories (Q: Dec. 2023 )) | / | count ) |
= | 3.79 | / ( | (6.112 | + | 5.522) | / | 2 ) |
= | 3.79 | / | 5.817 | ||||
= | 0.65 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rigel Pharmaceuticals (NAS:RIGL) Inventory Turnover Explanation
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Rigel Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Dec. 2023 ) | / | Cost of Goods Sold (Q: Dec. 2023 ) | * | Days in Period |
= | 5.817 | / | 3.79 | * | 365 / 4 | |
= | 140.05 |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Rigel Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Dec. 2023 ) | / | Revenue (Q: Dec. 2023 ) |
= | 5.817 | / | 35.792 | |
= | 0.16 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.
Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Raul R Rodriguez | officer: Sr VP of Bus Dev and Com Ops | 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
David A Santos | officer: EVP, Chief Commercial Officer | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080 |
Wolfgang Dummer | officer: EVP & CMO | 5491 OPTICAL CT., SAN JOSE CA 95138 |
Dean L Schorno | officer: EVP & Chief Financial Officer | 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
Raymond J. Furey | officer: EVP, GC & Corp Sec | 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807 |
Alison L. Hannah | director | 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913 |
Gary A Lyons | director | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
Anthony Gregg Lapointe | director | PO BOX 83216, GAITHERSBURG MD 20883-3216 |
Brian L. Kotzin | director | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94060 |
Kamil Ali-jackson | director | C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355 |
Jane Wasman | director | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Nelson Cabatuan | officer: Principal Accounting Officer | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080 |
Anne-marie Duliege | officer: Chief Medical Officer | 4001 MIRANDA AVENUE, PALO ALTO CA 94304 |
Mayer Eldon C. Iii | officer: EVP & Chief Commercial Officer | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080 |
Stacy Markel | officer: EVP Human Resources | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By PRNewswire • 07-05-2023
By PRNewswire • 08-01-2023
By PRNewswire PRNewswire • 05-02-2023
By PRNewswire PRNewswire • 05-31-2023
By PRNewswire PRNewswire • 04-25-2023
By PRNewswire PRNewswire • 06-06-2023
By PRNewswire • 08-30-2023
By PRNewswire • 11-14-2023
By PRNewswire • 01-04-2024
By PRNewswire • 10-11-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.